Please assess the completion status of the following clinical trial:

Trial Title: Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the prostate~* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care~* Patients, even if surgically sterilized (i.e., status post vasectomy), who agree to practice effective barrier contraception during the entire study treatment period and for 4 months after the last dose of study drug, or~* Agree to completely abstain from intercourse~* Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =\< 2.5 x the upper limit of normal (ULN)~* Total bilirubin =\< 1.5 x ULN~* Estimated creatinine clearance using the Cockcroft-Gault formula must be \> 40 mL/minute~* Absolute neutrophil count (ANC) \>= 1500 cells/microliter~* Platelet count \>= 100,000 cells/microliter~* Testosterone \< 50 ng/dL~* Screening calculated ejection fraction of \>= 50% by multiple gated acquisition (MUGA) scan or echocardiogram; metastatic progression on primary androgen-deprivation therapy (medical or surgical castration)~* Progression requiring a change in oncologic therapy defined by any of the following:~  * Radiographic progression: appearance or increase in measurable lesions on cross-sectional imaging or appearance of one or more new lesions on bone scan \* Rising PSA (\>= 2 ng/ml) which has risen on two occasions \>= 1 week apart~ * Clinical progression evidenced by increased pain or other cancer-related symptoms~* Patients should have recovered from prior oncologic therapies to a Common Terminology Criteria (CTC) grade =\< 1 except stable neuropathy or alopecia at National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade =\< 2; if rapid clinical progression is documented by imaging, changes in PSA, or symptoms, then study treatment can begin \>= 2 weeks from prior therapy; otherwise, the following time periods between prior anti-cancer therapies and study treatment day 1 will apply:~  * \>= 3 weeks for prior cytotoxic therapies~ * \>= 4 weeks for flutamide or nilutamide~ * \>= 6 weeks for bicalutamide~ * \>= 6 weeks since bone targeted radiopharmaceutical (e.g. samarium-153, radium-223)~* Gonadotropin-releasing hormone (GnRH) agonists (leuprolide acetate, goserelin, etc.) or antagonists (degarelix, etc.) should be continued in patients without surgically-induced castrate androgen levels~* For chemotherapy naïve castration-resistant prostate cancer who are moderately symptomatic or who have hepatic metastasis: subjects must not be a candidate for docetaxel-based chemotherapy.~Exclusion Criteria:~* History of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias of grade \> 2 (NCI CTCAE, version 4), thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g. pericardial effusion, restrictive cardiomyopathy) within 6 months prior to first dose of study drug; chronic stable atrial fibrillation on stable anticoagulant therapy is allowed~* New York Heart Association class III or IV heart failure~* Electrocardiogram (ECG) abnormalities of:~  * Q-wave infarction, unless identified 6 or more months prior to screening~ * Corrected QT (QTc) interval \> 460 msec~* Patient has received other investigational drugs within 28 days before enrollment~* Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy~* Known hypersensitivity to compounds related to TAK-700 or to TAK-700 excipients~* Uncontrolled hypertension despite appropriate medical therapy (blood pressure \[BP\] of greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the screening visit); Note: patients may be rescreened after adjustment of antihypertensive medications~* Known active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with participation in this study~* Likely inability to comply with the protocol or cooperate fully with the investigator and site personnel~* Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of TAK-700, including difficulty swallowing tablets~* Prior treatment with \>= 3 lines of cytotoxic chemotherapy for metastatic prostate cancer~* Prior treatment with TAK-700

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (orteronel) (Type: EXPERIMENTAL): Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility